This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

Charles Marwick

JAMA. 1999;282:516-517.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Washington—The system that attempts to protect subjects in clinical research is heading for a major overhaul. Its purported protections are insufficient and irregularly applied. It's time for a change, says a preliminary report from the National Bioethics Advisory Commission.

As an initial step, pressure is mounting within and outside the commission to give the Office of Protection From Research Risks (OPRR), which is currently located in the National Institutes of Health (NIH), a more prominent role in monitoring clinical research by elevating it to a position within the Department of Health and Human Services (DHHS). Moves are also in the offing to create a "national office of human subjects in research" that would effectively ensure that everyone participating in clinical research—not just those in federally funded studies—is properly protected. At least half the clinical research studies in the United States are funded by private sources, industry or . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Inside Information: Financial Conflicts of Interest for Research Subjects in Early Phase Clinical Trials
Helft et al.
JNCI J Natl Cancer Inst 2004;96:656-661.
ABSTRACT | FULL TEXT